FEXUCLUE
Live / Registered — Registered (as of 29 Nov 2022)
What this means for you
Registered since 29 Nov 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79314001
- Registration number
- 6908928
- Mark type
- Stylized text
- Filed
- 13 May 2021
- Published for opposition
- 13 Sept 2022
- Registered
- 29 Nov 2022
- Attorney of record
- Diane J. Mason
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents affecting digestive organs for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for the treatment of gastrointestinal diseases; Medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
Owner
Prosecution history
- 10 Nov 2023 — NEW REPRESENTATIVE AT IB RECEIVED
- 12 Apr 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Mar 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 21 Mar 2023 — FINAL DISPOSITION PROCESSED
- 28 Feb 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 29 Nov 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 29 Nov 2022 — REGISTERED-PRINCIPAL REGISTER
- 03 Oct 2022 — NOTIFICATION PROCESSED BY IB
- 13 Sept 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Sept 2022 — PUBLISHED FOR OPPOSITION
- 07 Sept 2022 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 07 Sept 2022 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 24 Aug 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Aug 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Aug 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED